Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized furosemide for acute dyspnea in EMS-transported adults
IRCT20151003024317N12Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of furosemide in Dyspnoea (SOB) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Acute dyspnea and Oxygen saturation. Started Nov 2020; status: completed.
02
Drugs
furosemide
03
Conditions
Dyspnoea (SOB)
Beyond the preview
Go deeper on IRCT20151003024317N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151003024317N12.